The Austin medtech building dissolving, plant-based hydrogels that keep healing tendons and nerves free to move.
ALAFAIR BIOSCIENCES, INC. - Headquartered at 6101 West Courtyard Drive, Austin, Texas. A commercial-stage medical device company founded by John Joyoprayitno and Sarah Mayes, PhD.
A surgery can go exactly right and still leave a patient stiff. When a repaired tendon or an exposed nerve fuses to the tissue around it, the scar-like tethering steals back the motion the operation was meant to restore. Alafair Biosciences has spent more than a decade on a single, unglamorous problem: give healing tissue room to glide.
The company, founded in Austin in 2011 by John Joyoprayitno and chemist Sarah Mayes, PhD, makes bioresorbable hydrogel implants that wrap or coat healing soft tissue and then dissolve once their job is done. No permanent hardware. No removal surgery. The result is a slippery, non-constricting interface that protects the microenvironment of a healing tendon or nerve and lets adjacent tissue planes slide past one another.
Its flagship device, VersaWrap, is a conformable, sutureless hydrogel sheet rich in hyaluronic acid. Its 2026 sibling, VersaCoat, delivers the same chemistry through a syringe for tight, minimally invasive spaces. Both are built on the company's VersaCore platform - a deliberately collagen-free, dye-free blend of naturally derived, high-molecular-weight hyaluronic acid and alginate.
The approach is finding an audience in operating rooms. VersaWrap has crossed 40,000 implants across orthopedic, spine, hand, lower-extremity and plastic and reconstructive procedures, and the company reported 722% year-over-year growth in 2025. It has appeared on the Inc. 5000 three years running.
"We're driven by a shared mission to improve healing and recovery for patients."John Joyoprayitno · President & CEO, Co-Founder
Postoperative adhesions - the unwanted binding of healing tissue to what surrounds it - are a well-known cause of stiffness, nerve tension and, sometimes, reoperation. A tendon that heals but can't glide, or a nerve that becomes tethered to nearby tissue, undermines the functional outcome patients actually care about.
Alafair's devices sit between tissue planes as a temporary, gliding barrier. By keeping surfaces from sticking during the critical healing window, they aim to reduce tethering, support earlier return of function, and lower the risk of a second operation.
Surgeon wraps VersaWrap around a tendon or nerve, or injects VersaCoat into tight anatomy.
The hydrogel forms a semi-permeable, non-constricting barrier around the healing tissue.
Adjacent tissue planes slide instead of sticking, limiting postoperative tethering.
Once healing is underway the device is fully absorbed - no hardware, no second surgery.
A conformable, sutureless, hyaluronic-acid-rich hydrogel sheet that encases injured or exposed tendons and peripheral nerves. FDA 510(k) cleared (K200311).
A syringe-deliverable version of the platform for complex, minimally invasive sites - a tissue-adherent gel that stays where applied and forms a gliding interface.
The underlying formulation: naturally derived high-molecular-weight hyaluronic acid and alginate in a collagen-free, dye-free, fully bioresorbable design.
Cumulative VersaWrap implants reported across company milestones. Figures are company-stated approximate totals.
Alafair is a B2B medical device manufacturer. It sells FDA-cleared, single-use Class II implants to hospitals, ambulatory surgery centers and health systems through a growing network of direct reps and distributors. Revenue is per-implant device sales, backed by a portfolio of 30 issued and 5 pending patents.
Its customers are surgeons: hand and upper-extremity, foot and ankle, spine, and plastic and reconstructive specialists who face the tethering problem routinely. Estimated annual revenue is in the low millions, with roughly 61 employees supporting national commercialization.
Alafair competes in the soft-tissue protection and anti-adhesion device space alongside larger players such as Axogen (nerve protection), Integra LifeSciences, Baxter (Seprafilm), Anika Therapeutics (hyaluronic-acid products), Collagen Matrix and Checkpoint Surgical.
Its differentiation is chemistry and philosophy: a collagen-free, plant-derived hydrogel that acts as a temporary gliding interface rather than a permanent barrier - and a two-format platform that reaches both open and minimally invasive procedures.
Two decades of medical-device leadership; named to Inc.'s Business Leader of the Year list in 2025.
Co-inventor of the proprietary VersaCore biomaterial and developer of the VersaWrap and VersaCoat formulations.
Broader team includes CFO Bhushan Holay, CRO Sean Knue, CMO Chris Sorensen, CDO Ben Walthall, PhD, and CBO David Wells.
John Joyoprayitno and Sarah Mayes, PhD, launch the company to commercialize biomaterials that improve internal wound healing, with support from UT Austin's technology incubator.
An oversubscribed financing round funds the next phase of commercialization for the hydrogel technology.
A plant-based, non-collagen, bioresorbable interface for tendon and peripheral nerve reaches the market following FDA 510(k) clearance.
VersaWrap passes a key adoption milestone across surgical specialties.
CEO John Joyoprayitno named Inc. Business Leader of the Year; company lands on Inc.'s Best in Business list.
The flowable hydrogel launches for minimally invasive use; total implants cross 40,000; named a 2026 Inc. Best Workplace.
The gel's building blocks are hyaluronic acid - found in your own joints and skin - and alginate, derived from seaweed.
Unlike most implants, it's designed to protect healing tissue and then fully bioresorb. No permanent hardware.
A deliberate departure from many traditional tissue barriers, which often rely on animal-derived collagen.
The company grew out of the University of Texas at Austin's technology incubator (ATI).
VersaCore is the platform, VersaWrap the sheet, VersaCoat the flowable gel - one idea, three forms.
722% growth came largely from surgeons coming back - word travels fast in an operating room.
Bioresorbable hydrogel implants - VersaWrap Hydrogel Sheet and VersaCoat Flowable Hydrogel - that protect healing tendons, nerves and other soft tissue after surgery to limit tethering and preserve motion.
It's built on VersaCore technology: a collagen-free, dye-free, fully bioresorbable blend of naturally derived high-molecular-weight hyaluronic acid and alginate.
Surgeons across orthopedic, spine, hand/upper-extremity, lower-extremity and plastic and reconstructive procedures. More than 40,000 VersaWrap implants have been used in patients.
Alafair Biosciences was founded in 2011 and is headquartered in Austin, Texas.
Yes - it's a Class II device with FDA 510(k) clearance (K200311).
Watch product demos and clinical interviews on the company's YouTube channel. Press releases and news are collected at alafairbiosciences.com/news.